Research on vaccination against SARS-CoV-2 and cross-saliva antibody

Research on vaccination against SARS-CoV-2 and cross-saliva antibody - Vaccination against SARS-CoV-2 and cross-saliva antibody

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043769

Enrollment

Registered

2021-03-30

Start date

2021-04-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Before and after vaccination against the new coronavirus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects were vaccinated against SARS-CoV-2, and 20 positive and 20 negative SARS-CoV-2 cross-reactive IgA were selected from Kanagawa Dental University Hospital workers in a previous study.

Exclusion criteria

Exclusion criteria: History of new coronavirus

Design outcomes

Primary

Measure	Time frame
Specimen search items, saliva S protein-specific sIgA, saliva S protein-specific IgG, S protein-specific IgM in saliva is measured by ELISA. The search method is as follows: (1) Perform a PCR test to detect SARS-CoV-2 in all search subjects and confirm that it is negative. Next, (2) collect saliva with saliva. Search before, 1 month and 6 months after vaccination.	—

Countries

Japan

Contacts

Public ContactKeiichi Tsukinoki

Kanagawa Dental University Graduate school of Dentistry

tsukinoki@kdu.ac.jp0468228866

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026